Rani Therapeutics Holdings (RANI) Debt to Equity (2020 - 2025)
Historic Debt to Equity for Rani Therapeutics Holdings (RANI) over the last 6 years, with Q3 2025 value amounting to -$1.13.
- Rani Therapeutics Holdings' Debt to Equity fell 12306.79% to -$1.13 in Q3 2025 from the same period last year, while for Sep 2025 it was -$1.13, marking a year-over-year decrease of 12306.79%. This contributed to the annual value of $7.05 for FY2024, which is 51019.37% up from last year.
- Rani Therapeutics Holdings' Debt to Equity amounted to -$1.13 in Q3 2025, which was down 12306.79% from -$1.88 recorded in Q2 2025.
- In the past 5 years, Rani Therapeutics Holdings' Debt to Equity ranged from a high of $7.05 in Q4 2024 and a low of -$3.91 during Q1 2025
- In the last 5 years, Rani Therapeutics Holdings' Debt to Equity had a median value of $0.28 in 2022 and averaged $0.89.
- As far as peak fluctuations go, Rani Therapeutics Holdings' Debt to Equity skyrocketed by 19969027.38% in 2023, and later plummeted by 29310.87% in 2025.
- Over the past 5 years, Rani Therapeutics Holdings' Debt to Equity (Quarter) stood at $0.0 in 2021, then surged by 37902.63% to $0.39 in 2022, then surged by 193.18% to $1.15 in 2023, then skyrocketed by 510.19% to $7.05 in 2024, then tumbled by 116.05% to -$1.13 in 2025.
- Its Debt to Equity stands at -$1.13 for Q3 2025, versus -$1.88 for Q2 2025 and -$3.91 for Q1 2025.